Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018577
Filing Date
2023-11-09
Accepted
2023-11-09 16:11:39
Documents
57
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nbse-20230930x10q.htm   iXBRL 10-Q 1417426
2 EX-31.1 nbse-20230930xex31d1.htm EX-31.1 13482
3 EX-31.2 nbse-20230930xex31d2.htm EX-31.2 13418
4 EX-32.1 nbse-20230930xex32d1.htm EX-32.1 9703
  Complete submission text file 0001558370-23-018577.txt   5851568

Data Files

Seq Description Document Type Size
5 EX-101.SCH nbse-20230930.xsd EX-101.SCH 42257
6 EX-101.CAL nbse-20230930_cal.xml EX-101.CAL 40967
7 EX-101.DEF nbse-20230930_def.xml EX-101.DEF 150115
8 EX-101.LAB nbse-20230930_lab.xml EX-101.LAB 397034
9 EX-101.PRE nbse-20230930_pre.xml EX-101.PRE 278830
51 EXTRACTED XBRL INSTANCE DOCUMENT nbse-20230930x10q_htm.xml XML 1015277
Mailing Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219
Business Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219 412-763-3350
NeuBase Therapeutics, Inc. (Filer) CIK: 0001173281 (see all company filings)

EIN.: 465622433 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35963 | Film No.: 231392523
SIC: 2834 Pharmaceutical Preparations